Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029548 | 0.86 | MEN1 (0.65) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL4137529 | 0.84 | MEN1 (0.63) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL8886414 | 0.83 | PTGDR2 (0.60) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL9952211 | 0.83 | KDM4E (0.65) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL8871879 | 0.81 | PTGDR2 (0.64) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL13738370 | 0.81 | MEN1 (0.56) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL15398988 | 0.81 | MEN1 (0.56) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL13737518 | 0.81 | MEN1 (0.56) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL15399743 | 0.81 | MEN1 (0.56) | MEN1KMT2AKDM4ELMNABDKRB2 | |
| SCHEMBL20179486 | 0.81 | NCF1 (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | MEN1 4131/4885KMT2A 3629/4885KDM4E 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.